Az Form 140: Fill & Download for Free

The AZ-140

A surge of 1000% in a small span of time is very common, but stocks holding those levels is very uncommon. The characteristic of sticking to those levels makes them, good stocks.If you check out the list of multibaggers of last few years, you will find almost 80% of those stocks are unable to hold that level. And they tumble down. So, I will discussing about the good ones in this answer:YES BANK:5 years ago the stocks of Yes bank were trading around a price of 59 with the face value of 10. In the span of these five years there has been a split in the stock from the face value of 10 to 2. Also, the stock has seen a major downfall of 50% in the last two months due to the change of CEO.Inspite of this the stock has given a return of 1339% in last 5 years.2. MINDA INDUSTRIES:This stock was trading around 11 rupees with face value of 10, 5 years back from now. During this time the stock has been split to a face value of 2 and also provided bonus of 2:1. The stock has witnessed a downfall of 40% from its 52 week high in the last two months. The reason for the fall being correction. And as all the small caps and mid caps have bled badly, this stock is no exception.This stock has given a return of 35000% in the last five years.3. BIOCON:This is a pharmaceutical company. Five years ago, the stocks of this company was trading around 140.In these five years the stock has given bonus of 2:1. Summing up all these the stock has generated a return of 1260%.All of the above stated stocks are of very good quality.For more information visit: protradingz.com

There are two vaccines available in quantity in the EU and UK at this time - the Oxford/AstraZeneca and BioNTech/Pfizer vaccines.The BioNTech/Pfizer mRNA vaccine, which is made by a predominantly chemical process is produced in only one plant in the world outside of the USA - Puurs in Belgium. That plant is contracted by Pfizer to supply the entire world outside of the US with the BioNTech vaccine.The Oxford/AstraZeneca genetically modified virus vaccine is made by what can loosely be termed a fermentation process and as it uses live material throughout is not as consistent in manufacture as the BioNTech vaccine. Like all such full virus vaccines, production needs to be ramped up as experience is gained with the process.Listening to Mairead McGuinness, an EU Trade Commissioner, talking this morning about the EU’s approach to vaccine exports, she stated that the EU had been ‘international not national’ in its approach. This was, at best, a half truth - the Pfizer plant is contracted to supply the whole world outside the US - it is its sole purpose.It is not some act of beneficence by the EU, but a contractual obligation by the plant’s owner, Pfizer.So, leaving that aside, which amounts to a high 90%+ of the 41 million doses exported that she was talking about, we are left with AstraZeneca and the Oxford vaccine.Prior to 2020 AZ had never made a vaccine before - this was their first attempt at such a procedure. They would have been much better off making the BioNTech vaccine, which better matched their skill set, but they built up the plant in the UK to actually produce the material - with a lot of financial support from the UK Government - and, after initial delays, are now working at full speed.They did not have the same advantages in continental Europe, where the order was late coming in and the same degree of assistance was not provided in establishing plant. As a result, AZ has been unusually dependent on third parties to get the job done, and that’s where most of the problems have occurred.At the same time, the Oxford vaccine has been licensed around the world and the Serum Insititute of India is now the largest manufacturer of the vaccine in the world - projected to be in the billions of doses this year.The EU is now looking at UK plant to make up a shortfall in the EU’s production, based on some loose wording in the original Terms of Supply from August 2020. The UK are not blocking any exports of either vaccines or precursors, but are simply sticking to their May 2020 contract with AZ which demands the first 100 million doses of the Oxford vaccine produced by the UK plant being for UK consumption.The EU is demanding that AstraZeneca break its contract with the UK so that it can take advantage of the fact that UK production is working as it should, while EU production is still beset with delays.UK production is currently sufficient to meet the UK need for first and second doses, but no more. There is no ‘spare’ to supply the EU with until this bad boy comes online in the autumn:-The VMIC will have a capacity of around 140 million doses a year and will truly revolutionize vaccine development and production in the UK, which, with the addition of further fill-and-finish facilities, will make us truly self-sufficient in vaccine production, of all types, and able to vaccinate the entire UK population every six months just from local production.